A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment

NCT00882908 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

386

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C

Interventions

DRUG: TMC435
DRUG: Ribavirin (R)
DRUG: PegIFNα-2a (P)
DRUG: Placebo

Sponsor

Tibotec Pharmaceuticals, Ireland